Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Canopy Growth

This 1 Cannabis Dividend Stock Yields 3%

You may not think about Constellation Brands as a marijuana stock, but it still has a huge stake in Canopy Growth.

Barchart

Canopy Growth (CGC) Stock Is Falling Wednesday: What's Going On?

Shares of Canopy Growth Corp (NASDAQ:CGC) are trading lower Wednesday, pulling back from a sharp rally on Monday. The stock is seeing a downturn as initial excitement wanes following a social media post by President Donald Trump over the weekend that lifted the entire cannabis sector.

Benzinga

As Trump Promotes CBD, Should You Buy, Sell, or Hold Canopy Growth Stock?

Canopy Growth stock rallies as President Donald Trump says cannabis could prove transformative for senior healthcare. But CGC shares remain unattractive to own in 2025.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Canopy Growth Stock a Buy, Sell, or Hold for September 2025?

Should investors buy, sell, or hold CGC stock after its recent stock resurgence?

Barchart

Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday.

Benzinga

Adult-Use Cannabis Boom Powers Canopy Growth Sales, But Wider Loss Hits Margins

Canopy Growth Corporation (NASDAQ:CGC) reported its first-quarter 2026 financial results on Friday, announcing a wider-than-expected loss despite surpassing revenue forecasts.

Benzinga

Canopy Growth Wraps Up Acreage Acquisition Expanding US Cannabis Portfolio, What Investors Need To Know

Canopy USA, LLC has wrapped up its acquisition of Acreage Holdings, Inc. (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), Canopy Growth Corporation's (TSX: WEED) (NASDAQ: CGC) U.S.-domiciled holding company said on Monday. Canopy USA, created in 2022 to streamline the Canadian cannabis giant's entry into the US market, now owns 100% of…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

Beyond Canada, this global cannabis company is focused on its international business, particularly in Germany, Australia, and the UK.

Benzinga

Canopy USA's Acquisition Of Acreage Could Mean Staggering Losses For Some Shareholders

Acreage Holdings, Inc. (CSE:ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF) said it anticipates that Canopy USA, LLC -Canopy Growth Corporation‘s (TSX: WEED) (NASDAQ: CGC) strategy for capturing the U.S. cannabis - will complete its acquisition of Acreage by mid-December, 2024.The move could leave holders of Acreage's Class E shares (fixed shares) with…

Benzinga

Canopy Growth Names New CEO Who Will Succeed David Klein Amid US Expansion

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) announced on Tuesday its board of directors has named Luc Mongeau as the company's next chief executive officer, effective Jan. 6, 2025.Mongeau, a CPG veteran and current board member at the Canadian cannabis giant, succeeds CEO David Klein, who announced his plans to…

Benzinga

Canopy Growth's German Subsidiary Teams Up With Portugal's Gro-Vida To Expand Medical Cannabis Supply

Portugal-based medical marijuana grower Gro-Vida teamed up with Canopy Growth Germany GmbH, a subsidiary of cannabis giant Canopy Growth Corporation (NASDAQ:CGC). This agreement is a key step for Gro-Vida to position itself in Germany’s growing medical marijuana market while supporting Canopy Growth GmbH’s strategy of securing EU-based supply through an…

Benzinga

2 'Strong Buy' Cannabis Stocks to Consider Instead of Canopy Growth

As the cannabis industry is poised for growth in 2024, top-rated Green Thumb Industries and Verano Holdings have emerged as attractive alternatives to struggling Canopy Growth. Both stocks have significant upside potential, and are making strategic moves that position them well in the evolving market.

Barchart

Up 100% YTD, Is Canopy Growth Stock Overbought?

Canopy Growth stock has surged over 100% in 2024. Despite its recent gains, CGC stock remains a high-risk bet, due to its weak fundamentals and negative profit margins.

Barchart

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Cannabis Stocks With More Upside Potential Than Canopy Growth

Three lesser-known cannabis companies are quietly making moves that could position them as more attractive investment opportunities than the headline-grabbing Canopy Growth.

Barchart

Why Are Canopy Growth (CGC) Options Soaring? It’s Politics, Baby!

It’s important to deal with reality. CGC stock is soaring because of election implications, not because the financials are so robust.

Barchart

2 Struggling Stocks to Skip After Reverse Splits

These two beaten-down stocks just climbed out of the penny stock basement, but they're still not the best names to buy for investors looking to speculate on upside in the EV and cannabis industries.

Barchart

Speculator Alert: Canopy Growth (CGC) May Live Up to Its Name

While practically every indicator out there suggests CGC stock is a market idea to dump right away, the options arena suggests otherwise.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

A Top-Rated Cannabis Stock That Could Surge in 2024

Far from a micro-cap, this spirits manufacturer offers a dividend alongside its stake in the cannabis industry, providing access to a rapidly growing market as legalization gains traction in the U.S. and abroad.

Barchart

3 Cannabis Stocks Analysts Like Better Than Canopy Growth

Discover three cannabis stocks with significant growth potential, and learn why analysts favor these names over Canopy Growth.

StockNews.com

What Lies Ahead for SNDL Inc. (SNDL) and Canopy Growth (CGC)?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in SNDL Inc. (SNDL) and Canopy Growth (CGC) now? Keep reading….

Barchart

3 Cannabis Stocks That Have More Upside Potential Than Canopy Growth, According to Wall Street Analysts

CGC has nearly tripled since late August - and now these three marijuana stocks have more upside potential, according to Wall Street.

StockNews.com

Canopy Growth (CGC) vs. Collegium Pharmaceutical (COLL): Which Pharma Stock Is the Better Buy for Growth Investors?

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

StockNews.com

Buy, Hold or Sell in July: Canopy Growth (CGC) and SNDL Inc. (SNDL)

Although the cannabis industry shows long-term growth potential, its near-term performance is hampered by intense regulations and limited financing. So, let's analyze whether you should Buy, Hold or Sell cannabis stocks SNDL (SNDL) and Canopy Growth (CGC).

StockNews.com

Is Canopy Growth (CGC) a Buy Under $2?

Canadian cannabis producer Canopy Growth (CGC) is making significant changes to its business model in an effort to turn profitable. However, given the regulatory challenges, will the company get success anytime soon? Let’s look at some of CGC’s metrics to understand if this penny stock is worth buying now.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.